Viemed Healthcare, Inc. (VMD) Income Statement
VMD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVMD revenue and net income
Where VMD's revenue goes
2025Each bar shows an amount and its share of revenue. VMD kept 5.5% of revenue as net income.
VMD profit margins
VMD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +20.5% | +24.9% | +15.5% | +21.8% |
| Gross profit | +16.7% | +22.4% | +14.2% | +18.3% |
| Operating income | +15.7% | +35.9% | −5.0% | +6.6% |
| Net income | +32.6% | +33.9% | −13.9% | +5.3% |
| EPS (diluted) | +15.6% | +35.1% | −13.9% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VMD quarterly EPS vs estimates
Viemed Healthcare beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $0.12).
VMD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $270.3M | $224.3M | $183.0M | $138.8M | $117.1M | $131.3M | $80.3M | $64.5M | $46.9M | $31.4M |
| Cost of revenue | $114.8M | $91.1M | $70.2M | $54.2M | $43.7M | $51.2M | $24.2M | $16.7M | $12.3M | $12.5M |
| Gross profit | $155.5M | $133.2M | $112.8M | $84.7M | $73.4M | $80.1M | $56.0M | $47.8M | $34.6M | $18.9M |
| Research & development | $3.0M | $3.1M | $2.8M | $2.7M | $2.1M | $1.1M | $848,000 | $848,000 | $848,000 | $848,000 |
| Sales, general & admin | $130.5M | $112.5M | $94.3M | $73.4M | $60.0M | $57.7M | $45.3M | $37.3M | $20.2M | $13.8M |
| Total operating expenses | $134.7M | $115.3M | $98.5M | $76.4M | $61.8M | $53.3M | $47.1M | $37.7M | $25.8M | $18.5M |
| Operating income | $20.7M | $17.9M | $14.3M | $8.3M | $11.6M | $26.8M | $8.9M | $10.1M | $8.8M | $383,000 |
| Interest income | — | — | — | — | — | — | $314,000 | $181,000 | $272,000 | $323,000 |
| Interest expense | $1.2M | $776,000 | $424,000 | $197,000 | $318,000 | $509,000 | $314,000 | $181,000 | $272,000 | $323,000 |
| Income before taxes | $21.8M | $16.2M | $14.4M | $9.0M | $12.5M | $26.4M | $8.8M | $9.7M | $8.2M | $109,000 |
| Income taxes | $6.4M | $4.8M | $4.1M | $2.8M | $3.4M | −$5.2M | $271,000 | $162,000 | $15,000 | −$1.1M |
| Net income | $14.9M | $11.3M | $10.2M | $6.2M | $9.1M | $31.5M | $8.5M | $9.5M | $8.2M | $1.2M |
| EBITDA | $51.6M | $42.3M | $36.7M | $24.8M | $24.1M | $36.5M | $15.5M | $13.9M | $11.4M | $1.8M |
| EPS (diluted) | $0.37 | $0.32 | $0.27 | $0.15 | $0.22 | $0.78 | $0.23 | $0.23 | $0.21 | $0.06 |
| Gross margin | 57.5% | 59.4% | 61.6% | 61.0% | 62.7% | 61.0% | 69.8% | 74.1% | 73.8% | 60.1% |
| Operating margin | 7.7% | 8.0% | 7.8% | 5.9% | 9.9% | 20.4% | 11.0% | 15.6% | 18.8% | 1.2% |
| Net margin | 5.5% | 5.0% | 5.6% | 4.5% | 7.8% | 24.0% | 10.6% | 14.7% | 17.4% | 3.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.1M | $75.4M | $76.2M | $71.9M | $63.1M | $59.1M | $60.7M | $58.0M | $55.0M | $50.6M | $50.7M | $49.4M |
| Cost of revenue | $33.4M | $33.0M | $32.1M | $30.6M | $26.7M | $25.9M | $24.6M | $23.6M | $22.1M | $20.8M | $18.6M | $18.8M |
| Gross profit | $44.7M | $42.4M | $44.1M | $41.3M | $36.4M | $33.3M | $36.1M | $34.4M | $32.9M | $29.8M | $32.1M | $30.6M |
| Research & development | $504,000 | $579,000 | $598,000 | $775,000 | $847,000 | $797,000 | $803,000 | $757,000 | $758,000 | $750,000 | $651,000 | $593,000 |
| Sales, general & admin | $39.2M | $37.2M | $34.5M | $34.1M | $31.1M | $30.7M | $29.7M | $28.4M | $28.3M | $26.2M | $26.1M | $25.1M |
| Total operating expenses | $39.6M | $37.7M | $35.4M | $35.2M | $31.9M | $29.4M | $29.7M | $28.7M | $29.3M | $27.6M | $26.8M | $26.4M |
| Operating income | $5.1M | $4.7M | $8.7M | $6.1M | $4.5M | $3.8M | $6.5M | $5.6M | $3.6M | $2.2M | $5.3M | $4.2M |
| Interest expense | $248,000 | $305,000 | $364,000 | $507,000 | $132,000 | $179,000 | $147,000 | $225,000 | $254,000 | $150,000 | $256,000 | $237,000 |
| Income before taxes | $4.1M | $4.0M | $8.0M | $5.1M | $5.0M | $3.7M | $6.3M | $5.5M | $2.2M | $2.1M | $5.1M | $4.2M |
| Income taxes | $1.2M | $1.3M | $2.2M | $1.5M | $1.7M | $952,000 | $1.9M | $1.6M | $768,000 | $518,000 | $1.6M | $1.3M |
| Net income | $2.8M | $2.6M | $5.6M | $3.5M | $3.2M | $2.6M | $4.3M | $3.9M | $1.5M | $1.6M | $3.5M | $2.9M |
| EBITDA | $12.6M | $11.9M | $15.9M | $13.2M | $12.0M | $8.2M | $11.7M | $12.1M | $9.4M | $8.6M | $11.3M | $10.5M |
| EPS (diluted) | $0.07 | $0.06 | $0.14 | $0.09 | $0.08 | $0.06 | $0.10 | $0.10 | $0.08 | $0.04 | $0.09 | $0.08 |
| Gross margin | 57.2% | 56.3% | 57.9% | 57.5% | 57.7% | 56.3% | 59.5% | 59.3% | 59.8% | 58.9% | 63.3% | 61.9% |
| Operating margin | 6.5% | 6.3% | 11.4% | 8.5% | 7.2% | 6.5% | 10.6% | 9.7% | 6.6% | 4.4% | 10.4% | 8.5% |
| Net margin | 3.5% | 3.4% | 7.4% | 4.9% | 5.0% | 4.4% | 7.1% | 6.7% | 2.7% | 3.2% | 6.9% | 5.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VMD's financial statements (latest annual report filed March 4, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VMD financial results
In fiscal year 2025 (ended December 31, 2025), Viemed Healthcare reported revenue of $270.3 million, up 20.5% from the year before. It had net income of $14.9 million (up 32.6%), a net profit margin of 5.5%. Diluted earnings per share came to $0.37. Over five years revenue grew at an average rate of 15.5% a year.
See the VMD stock overview for the latest quote and news, or the VMD chart for price history and technical indicators.
VMD income statement FAQ
What is Viemed Healthcare's annual revenue?
Viemed Healthcare reported total revenue of $270.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 20.5% from $224.3 million the previous year.
Is Viemed Healthcare profitable?
Yes. Viemed Healthcare reported net income of $14.9 million in fiscal 2025, a net profit margin of 5.5%; its operating margin was 7.7%.
What is Viemed Healthcare's gross margin?
Viemed Healthcare's gross margin was 57.5% in fiscal 2025: for every $100 of revenue, Viemed Healthcare kept $58 after the direct cost of its products and services.
How much does Viemed Healthcare spend on research and development?
Viemed Healthcare spent $3.0 million on research and development in fiscal 2025, 1.1% of revenue.
How fast is Viemed Healthcare growing?
Revenue grew 15.5% a year on average over the last five fiscal years, from $131.3 million to $270.3 million.
What are Viemed Healthcare's earnings per share?
Viemed Healthcare earned $0.37 per diluted share in fiscal 2025, compared with $0.32 a year earlier.
When will Viemed Healthcare report its next earnings?
Viemed Healthcare is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Viemed Healthcare's fiscal year end?
Viemed Healthcare's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 4, 2026.